[OBSERVATIONS ON THE USE OF PHENYLPYRROLIDINOPENTANE AS AN ANTIASTHENIC AGENT IN TREATMENT WITH PSYCHOPHARMACOLOGICAL DRUGS].
D000639:Amitriptyline; D001007:Anxiety; D001008:Anxiety Disorders; D001247:Asthenia; D001714:Bipolar Disorder; D056486:Chemical and Drug Induced Liver Injury; D002746:Chlorpromazine; D003863:Depression; D003975:Diazepam; D005476:Fluphenazine; D006505:Hepatitis; D001523:Mental Disorders; D008996:Monoamine Oxidase Inhibitors; D009497:Neurotic Disorders; D011395:Promazine; D011600:Psychopharmacology; D012559:Schizophrenia; D013566:Sympathomimetics; D014116:Toxicology; D014149:Tranquilizing Agents
D008996:Monoamine Oxidase Inhibitors; D013566:Sympathomimetics; D014149:Tranquilizing Agents; D000639:Amitriptyline; D011395:Promazine; D003975:Diazepam; D005476:Fluphenazine; D002746:Chlorpromazine
AMITRIPTYLINE; ASTHENIA; CHLORPROMAZINE; DEPRESSION; DIAZEPAM; FLUPHENAZINE; HEPATITIS, TOXIC; MENTAL DISORDERS; MONOAMINE OXIDASE INHIBITORS; NEUROSES, ANXIETY; PROMAZINE; PSYCHOSES, MANIC-DEPRESSIVE; SCHIZOPHRENIA; SYMPATHOMIMETICS; TOXICOLOGIC REPORT; TRANQUILIZING AGENTS
OSSERVAZIONI SULL'IMPIEGO DEL FENILPIRROLIDINOPENTANO COME ANTIASTENICO DURANTE TRATTAMENTO CON PSICOFARMACI.